H. Lundbeck A/S and Otsuka Pharmaceutical Co. Ltd., co-developers of the atypical antipsychotic brexpiprazole, said that during two global phase III trials the medicine failed to prove statistically better than a placebo in reducing symptoms of mania for adults with bipolar I disorder. The companies, which already sell brexpiprazole as Rexulti for the adjunctive treatment of major depressive disorder and as a maintenance treatment for schizophrenia, said they will conduct an analysis of the study results to determine next steps.